Core Viewpoint - The company is actively positioning itself in the synthetic biology manufacturing industry, achieving domestic leadership in the industrialization of human milk oligosaccharides, specifically LNT and LNnT [1] Group 1 - Since 2025, the company has made significant progress in key areas such as research and development, production operations, quality system construction, regulatory submissions, and strain optimization for human milk oligosaccharide products [1] - The company's production base in Zhuhai has recently completed factory inspections for several domestic dairy enterprises [1]

Group 1: Company Overview and Financial Performance - The company achieved a revenue of 1.386 billion yuan in the first three quarters of 2025, a year-on-year increase of 0.17% [3] - Net profit attributable to shareholders reached 249 million yuan, reflecting a significant year-on-year growth of 28.89% [3] - In Q3 2025, revenue was 532 million yuan, showing a year-on-year growth of 8.31%, while net profit was 102 million yuan, up 39.55% year-on-year [3] Group 2: Business Strategies and Technological Advantages - The increase in performance is attributed to improved gross margins due to effective cost control measures and rising UCO prices [3] - The company utilizes core biological enzyme technology for large-scale production of bioenergy, achieving higher conversion rates without harmful chemicals [4] - The anaerobic microorganism technology enhances waste degradation efficiency and gas production, contributing to increased operational profits [4] - AI technology is applied in waste collection to improve operational efficiency and data tracking [4] Group 3: Market Position and Product Development - The company has adjusted its sales strategy for bioenergy products in response to rising SAF and UCO prices, focusing on direct sales of UCO [5] - The company is actively developing synthetic biology manufacturing, achieving commercialization of specific human milk oligosaccharides (HMOs) [7] - The company has a competitive edge in the HMO market due to advanced approval processes, high product purity, and optimized production techniques [7] - Recent approvals from the National Health Commission for two types of HMOs expand their application in infant formula and other products [7]

Group 1 - The company holds a 2% stake in the Shenzhen Biomanufacturing Industry Innovation Center, which is the only national-level synthetic biology industry innovation center approved by the National Development and Reform Commission [2] - The company's core business focuses on two main areas: synthetic biological manufacturing and biomass resource regeneration, with synthetic biology being the strategic focus [2]

Core Viewpoint - Longkun Technology (301305.SZ) reported strong financial performance for Q3 2025, with significant year-on-year growth in both revenue and net profit, driven primarily by the sustainable aviation fuel (SAF) market and rising prices of used cooking oil (UCO) [1][2][3] Financial Performance - For the first three quarters of 2025, Longkun Technology achieved a revenue of 1.39 billion yuan, a year-on-year increase of 0.2%, and a net profit attributable to shareholders of 250 million yuan, up 28.9% [1] - In Q3 2025, the company reported a revenue of 530 million yuan, reflecting an 8.3% year-on-year growth, and a net profit of 100 million yuan, which is a 39.6% increase compared to the same period last year [1] - The company's Q3 performance set historical highs for both quarterly and year-to-date results, significantly exceeding market expectations [1] Market Dynamics - The demand for SAF has surged due to regulatory policies mandating blending of aviation fuel in various countries, leading to increased competition for raw materials [2] - As of October 2025, the price of UCO abroad reached $1,116 per ton, a 12% increase since the beginning of the year, while domestic prices for waste cooking oil have risen to 6,850 yuan per ton, a 19% increase [2] Business Operations - Longkun Technology is a key player in the UCO market, leveraging its comprehensive waste oil collection and processing system to enhance profitability [3][4] - Approximately 55% of the company's revenue and 52% of its gross profit in the first half of 2025 came from bioenergy products, with rising UCO prices positively impacting profit margins [3] - The company operates 35 biomass resource regeneration projects, with 21 already in operation, and holds the leading market share in major cities like Beijing, Shenzhen, and Guangzhou [4] Strategic Initiatives - In 2023, Longkun Technology initiated a significant strategic transformation towards biotechnology, focusing on synthetic biological manufacturing [5] - The company’s subsidiary, Longjian Biotechnology, has received approval for its human milk oligosaccharides (HMOs) product, positioning it as the first domestic enterprise to achieve this milestone [5] - The HMO project is expected to scale production by 2026, tapping into the growing market for high-value nutritional components as consumer awareness of "precision nutrition" increases [5]

Core Viewpoint - The company reported a slight decline in revenue but a significant increase in net profit, driven by improvements in core business efficiency [2][3] Revenue and Profit Performance - In the first half of 2025, the company achieved operating revenue of 855 million yuan, a year-on-year decrease of 4%, while net profit attributable to shareholders reached 147 million yuan, a year-on-year increase of 22% [1][2] - The net profit after deducting non-recurring items was 145 million yuan, reflecting a year-on-year growth of 25.43% [2] Business Segment Analysis - The bioenergy (biodiesel) segment was a key driver of profit growth, generating revenue of 474 million yuan, up 6.38% year-on-year, with a significant reduction in operating costs by 7.22%, leading to a gross margin increase of 9.71 percentage points to 33.77% [2][3] - The traditional biomass waste operation service business also showed steady growth, achieving revenue of 314 million yuan, a year-on-year increase of 12.11% [3] Synthetic Biology Business Development - The synthetic biology manufacturing business made significant progress, with LNT and LNnT products receiving Self-GRAS certification in the U.S., paving the way for market expansion [4] - The company has completed fermentation production of 30 tons of LNnT and is advancing the development of various HMO products [4] Future Earnings Forecast - The company is projected to achieve operating revenues of 2.293 billion, 2.882 billion, and 3.625 billion yuan for 2025-2027, with year-on-year growth rates of 28.03%, 25.68%, and 25.81% respectively [5] - Net profit attributable to shareholders is expected to be 302 million, 405 million, and 519 million yuan for the same period, with growth rates of 40.07%, 34.12%, and 28.19% respectively [5]

Core Viewpoint - Longkun Technology reported a stable performance in its 2024 annual report, with total revenue of 1.791 billion yuan, a year-on-year increase of 2.18%, and a net profit attributable to shareholders of 216 million yuan, up 20.51% year-on-year. However, the bioenergy segment faced challenges due to an EU anti-dumping investigation, resulting in a 19.41% decline in revenue from this segment. The company is focusing on technological innovation and market expansion to mitigate these challenges and is accelerating its layout in synthetic biology manufacturing to capture a larger market share in the green economy and health industry [1][4][7]. Group 1: Biomass Resource Recycling Business - Longkun Technology has secured multiple significant projects in the biomass resource recycling sector, including a 25.5023 million yuan project in Beijing and a 1.654 billion yuan project in Tongzhou District, which has a processing capacity of 2,100 tons per day and a concession period of 40 years [4]. - Despite the success in project bidding, the bioenergy business has been impacted by the EU's anti-dumping investigation, which imposed a temporary anti-dumping tax of 23.7%, leading to a 19.41% decline in bioenergy revenue [4][6]. - The management indicated that the profit from the biodiesel business primarily comes from self-produced low-cost raw oil, suggesting that market changes have a limited impact on overall operations [4]. Group 2: Synthetic Biology Manufacturing Business - Longkun Technology is actively developing the human milk oligosaccharides (HMOs) sector, collaborating with institutions like the Hefei Institute of Physical Science to advance products such as LNT and LNnT [5][6]. - The company has made significant progress in product certification and market access, with LNnT receiving approval as a new food additive from the National Health Commission and 2'-FL obtaining Self-GRAS certification from the FDA [6][7]. - The establishment of a 1,000-ton HMO production base is underway, with the first phase expected to begin trial production in the first half of 2025 [6]. Group 3: Profit Model - Longkun Technology's profit model is diversified, comprising biomass resource recycling and synthetic biology manufacturing. The company utilizes BOT and BOO models to charge waste treatment fees and sell biodiesel and green electricity [7]. - In 2024, engineering construction revenue surged by 137.82% to 418 million yuan, while operational service revenue increased by 8.57% to 581 million yuan, indicating stable growth despite the decline in bioenergy revenue [7]. - The synthetic biology manufacturing segment is expected to become a new profit growth point as products gain market access, contributing to a 32.07% year-on-year increase in non-net profit [7].

Core Insights - The company reported a significant increase in net profit and improved cash flow, driven by new project wins and stable operational growth [2] - The company achieved a revenue of 1.791 billion yuan in 2024, a 2% year-on-year increase, and a net profit of 216 million yuan, a 21% increase [1][2] - In Q1 2025, the company reported a revenue of 412 million yuan, a 16% year-on-year decline, but a net profit of 77 million yuan, a 95% increase [1][2] Revenue Breakdown - Engineering construction revenue reached 418 million yuan, a 138% year-on-year increase, with a gross margin of 17.72%, down 1.82 percentage points [2] - Operational services generated 581 million yuan, a 9% year-on-year increase, with a gross margin of 41.43%, down 0.47 percentage points [2] - Bioenergy revenue was 786 million yuan, a 19% year-on-year decline, but the gross margin improved by 9.12 percentage points to 27.44% [2] Cash Flow Improvement - Operating cash flow significantly improved, reaching 391 million yuan, a 246% year-on-year increase [2] Environmental Projects - The company has 35 biomass resource regeneration projects, with 21 already operational [3] - New major environmental project wins include a 1.654 billion yuan biomass waste resource processing center in Beijing and a 736 million yuan biomass resource regeneration center [3] Synthetic Biology Developments - The company made significant progress in the field of human milk oligosaccharides (HMOs), achieving industry-leading product purity [4] - Regulatory approvals for LNnT and LNT have been obtained, with production capacity expected to ramp up in the coming years [4] Profit Forecast - Revenue projections for 2025-2027 are 2.293 billion, 2.882 billion, and 3.625 billion yuan, with year-on-year growth rates of 28.03%, 25.68%, and 25.81% respectively [5] - Net profit forecasts for the same period are 319 million, 436 million, and 599 million yuan, with growth rates of 48.19%, 36.63%, and 37.24% respectively [5]